Follow the science.
Find your starting point.

Source checked · 2026-10-27

Small-molecule NNMT inhibitor, not a peptide. Cell and obese-mouse findings do not establish human dosing, oral pharmacokinetics or treatment outcomes; US product status remains unassessed.

Source checked · 2026-10-27

Oral obesity studies and later LAT8881 pain trials are human research, with no established routine injection benefit. FDA states the assessed free-base/acetate forms are not approved-drug components; GRAS food claims are separate.

Source checked · 2026-10-27

Cibinetide is an 11-amino-acid EPO-derived peptide. Small sarcoidosis trials show selected nerve-fiber signals but not consistent between-group pain benefit; serious adverse events and short follow-up limit safety conclusions. US product records not fully adjudicated.

Source checked · 2026-10-27

Small topical wrinkle trials are positive; penetration is formulation-dependent and clinical Botox equivalence is unestablished. The 2025 expert-panel safety conclusion is bounded to described use up to 0.005% active, not unlimited strength. Complete current US product status not adjudicated.

Source checked · 2026-10-27

Limited human reports and a rectal-trial account do not establish a general treatment effect. FDA states the assessed free-base and acetate forms are not components of approved drugs; pending policy review is separate.

Source checked · 2026-10-27

Human mixture studies include positive rehabilitation and TBI findings, neutral acute-stroke outcomes and safety qualifications. Austrian product information and manufacturer US nonapproval statements are not an independent current FDA adjudication.

Source checked · 2026-10-26

A related CJC reference route, with long-acting hormone data and unresolved product-form questions.

Source checked · 2026-10-26

Short GH/IGF-I studies concern long-acting material; DAC and salt identities matter.

Source checked · 2026-10-27

Selected oral skin/joint/bone trials are positive, with neutral endpoints and material-specific doses. A 2025 skin meta-analysis raises quality/funding concerns; later positive trials remain separate. Nutritional mixtures differ from injected products; current US product records not fully adjudicated.

Source checked · 2026-10-27

Mixed animal findings: the 2014 mechanism paper was retracted in 2025, and the 2013 development paper has a 2021 notice of concern. No validated human dosing or cognitive efficacy was identified in the reviewed sources; US product records were not fully adjudicated.

Source checked · 2026-10-27

Small human IV studies show mixed sleep findings; subcutaneous and long-term outcomes remain separate. FDA states the assessed emideltide free-base/acetate forms are not approved-drug components.

Source checked · 2026-10-26

Trulicity evidence concerns type 2 diabetes; this is not a weight-loss indication.

Source checked · 2026-10-27

Small retinal and circadian-biomarker reports do not demonstrate longer human lifespan or clinical insomnia relief. FDA’s 2026 assessment distinguishes free base and acetate and states neither is an approved-drug component; compounding policy is separate.

Source checked · 2026-10-27

Byetta and Bydureon BCise have type 2 diabetes indications, different dosing and product-specific warnings. Weight changes are not an obesity approval; EXSCEL met cardiovascular noninferiority but not superiority.

Source checked · 2026-10-27

Small human gene-transfer studies report some walking/biopsy benefits, neutral outcomes and design limits. Gene vectors, processed isoforms and injected protein are different interventions; newer plasmid registrations have no posted results. Current US protein-product status was not fully adjudicated.

Source checked · 2026-10-27

Original academic cell/mouse research reports selected tissue-function and frailty-related benefits, not human aging reversal. Exact-term ClinicalTrials.gov search returned no studies with search limits; no clinical nasal/subcutaneous regimen or complete current US product adjudication.

Source checked · 2026-10-27

Formulation-specific topical human results, including a small eyebrow study, do not establish injectable efficacy. FDA Category 1 context excludes injectable routes; no approval status inferred.

Source checked · 2026-10-26

Diagnostic and food-intake experiments do not establish a routine weight-loss or performance regimen.

Source checked · 2026-10-26

Acute human hormone/sleep results and preclinical findings answer different questions.

Source checked · 2026-10-27

FDA human Factrel and Lutrepulse application products are discontinued in the reviewed dataset. Pulsatile-pump infertility research and dated Canadian product information do not validate occasional TRT add-on injections or establish current US supply.

Source checked · 2026-10-26

Human hormone, sleep and acute cardiac studies do not establish a routine muscle-building, sleep or chronic cardiac treatment.

Source checked · 2026-10-27

Cell and animal treatment findings; human comparisons are biomarkers, not administered-human efficacy trials. HNG increased some metabolic measures but did not significantly extend female mouse lifespan. No validated human regimen or complete US product adjudication.

Source checked · 2026-10-27

LR3 cell and rat findings are distinct from native IGF-I and the mecasermin label. Human muscle-gain estimates and a 20–30-hour human half-life are not established by the cited studies; LR3 US product status not inferred from mecasermin.

Source checked · 2026-10-26

Human IV studies and preclinical selectivity do not establish chronic home-injection safety.